Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,323Revenue $M64.5Net Margin (%)12.2Z-Score1.1
Enterprise Value $M1,328EPS $0.6Operating Margin %29.2F-Score6
P/E(ttm))212Cash Flow Per Share $0.6Pre-tax Margin (%)11.2Higher ROA y-yN
Price/Book30.510-y EBITDA Growth Rate %0Quick Ratio10.7Cash flow > EarningsY
Price/Sales22.45-y EBITDA Growth Rate %0Current Ratio10.8Lower Leverage y-yN
Price/Cash Flow32.1y-y EBITDA Growth Rate %27.1ROA % (ttm)5.0Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)7ROE % (ttm)12.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M19.7ROI % (ttm)10.2Gross Margin Increase y-yY

Gurus Latest Trades with LGND

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LGNDKen Fisher 2014-12-31 Add0.01%$42.36 - $57.96
($52.23)
$ 67.5529%Add 132.31%81,908
LGNDJoel Greenblatt 2014-12-31 Reduce-0.26%$42.36 - $57.96
($52.25)
$ 67.5529%Reduce -99.32%3,766
LGNDJoel Greenblatt 2014-09-30 Add0.23%$46.99 - $64.52
($53.04)
$ 67.5527%Add 894.83%552,053
LGNDJoel Greenblatt 2014-06-30 Buy 0.04%$59.74 - $70.19
($65.09)
$ 67.554%New holding, 55492 sh.55,492
LGNDKen Fisher 2014-06-30 Buy $59.74 - $70.19
($65.09)
$ 67.554%New holding, 36908 sh.36,908
LGNDJoel Greenblatt 2014-03-31 Sold Out -0.02%$51.52 - $79.58
($66.37)
$ 67.552%Sold Out0
LGNDJoel Greenblatt 2013-12-31 Add0.01%$44.86 - $57.95
($52.33)
$ 67.5529%Add 124.95%13,803
LGNDJoel Greenblatt 2013-09-30 Buy 0.01%$38.69 - $49.66
($45.21)
$ 67.5549%New holding, 6136 sh.6,136
LGNDDaniel Loeb 2011-12-31 Sold Out -0.46%$10.59 - $15.73
($12.77)
$ 67.55429%Sold Out0
LGNDGeorge Soros 2011-09-30 Sold Out -0.0017%$10.89 - $15.95
($13.18)
$ 67.55412%Sold Out0
LGNDDaniel Loeb 2011-06-30 Add0.16%$9.56 - $12.02
($10.55)
$ 67.55540%Add 110.73%705,016
LGNDGeorge Soros 2011-06-30 Buy $9.56 - $12.02
($10.55)
$ 67.55540%New holding, 10000 sh.10,000
LGNDGeorge Soros 2009-12-31 Sold Out $9.96 - $14.16
($12.06)
$ 67.55460%Sold Out0
LGNDGeorge Soros 2009-09-30 Buy $13.74 - $18.9
($16.26)
$ 67.55315%New holding, 26900 sh.26,900
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LGND is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
LGND Ken Fisher 2014-12-3181,9080.420.01+132.31%
LGND Joel Greenblatt 2014-12-313,7660.020-99.32%
Premium Most recent portfolio changes are included for Premium Members only!


LGND: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Herman Melanie JDirector of Accounting 2015-02-19Sell510$57.845.45view
DeSilva Nishan MVP, Corporate Development 2015-02-10Sell2,300$56.348.25view
Herman Melanie JDirector of Accounting 2014-12-31Buy103$45.2334.84view
FOEHR MATTHEW WEVP and COO 2014-12-31Buy46$45.2334.84view
Berkman Charles SVP, Gen. Counsel & Secretary 2014-12-31Buy126$45.2334.84view
KOZARICH JOHN WDirector 2014-10-15Buy2,000$45.6833.52view
FOEHR MATTHEW WEVP and COO 2014-10-10Buy85$44.9135.8view
KNOTT DAVID MDirector 2014-10-09Buy4,000$43.0141.8view
Sabba Stephen LDirector 2014-10-09Buy2,000$43.1241.44view
Aryeh JasonDirector 2014-10-09Buy11,000$42.9941.87view

Press Releases about LGND :

    Quarterly/Annual Reports about LGND:

    News about LGND:

    Articles On GuruFocus.com
    dick Feb 13 2015 
    Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
    5 Hot Stocks to Consider Now Mar 30 2012 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
    Ligand to Acquire Neurogen for Stock and Contingent Value Rights Aug 24 2009 
    Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 
    Ligand Pharmaceuticals Announces Second Quarter Results Aug 03 2009 
    Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results Feb 12 2009 

    More From Other Websites
    10-K for Ligand Pharmaceuticals, Inc. Feb 25 2015
    LIGAND PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 23 2015
    Glaxo Submits Another Revolade Application in the EU - Analyst Blog Feb 09 2015
    Ligand Pharmaceuticals (LGND) Posts In-Line Q4 Earnings - Tale of the Tape Feb 09 2015
    LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Feb 09 2015
    Ligand meets 4Q profit forecasts Feb 09 2015
    Ligand meets 4Q profit forecasts Feb 09 2015
    Ligand Reports Fourth Quarter and Full Year 2014 Financial Results Feb 09 2015
    Ligand Reports Fourth Quarter and Full Year 2014 Financial Results Feb 09 2015
    Q4 2014 Ligand Pharmaceuticals Inc Earnings Release - Before Market Open Feb 09 2015
    Will Ligand Pharmaceuticals (LGND) Miss on Earnings in Q4? - Analyst Blog Feb 06 2015
    Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission Seeking Additional Indication for... Feb 06 2015
    Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission Seeking Additional Indication for... Feb 06 2015
    Ligand Signs License Agreement with Sermonix for Lasofoxifene Feb 03 2015
    LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation... Feb 02 2015
    Ligand Promotes Matthew W. Foehr to President Feb 02 2015
    Ligand to Present at BIO CEO and RBC Capital Markets Global Healthcare Conferences in February Jan 28 2015
    Ligand to Report Fourth Quarter Results on February 9th Jan 27 2015
    Ligand to Report Fourth Quarter Results on February 9th Jan 27 2015
    Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan Jan 09 2015
    Healthtech: Portland biotech raises $350K from private investors Jan 08 2015
    Ligand Partner Melinta Therapeutics Reports Positive Phase 3 Results for Captisol-enabled™... Jan 08 2015
    Ligand Partner Melinta Therapeutics Reports Positive Phase 3 Results for Captisol-enabled™... Jan 08 2015
    Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for... Dec 26 2014
    Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for... Dec 26 2014
    Spectrum Pharmaceuticals Files a New Drug Application with the FDA for Captisol-Enabled™... Dec 26 2014
    Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for... Dec 22 2014
    Ligand Partner GlaxoSmithKline Announces US Regulatory Submission Seeking Additional Indication for... Dec 22 2014
    Ligand Partner Pfizer Receives European Marketing Authorization for DUAVIVE® (Conjugated... Dec 19 2014
    Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission for Severe Aplastic Anemia... Nov 12 2014
    Ligand Reports Third Quarter 2014 Financial Results Oct 27 2014
    Ligand beats Street 3Q forecasts Oct 27 2014
    Ligand to Report Third Quarter 2014 Financial Results Oct 27 2014
    Ligand to Host Analyst Day on November 18th in New York City Oct 16 2014
    Ligand Earns $1 Million Milestone Payment Triggered by FDA Approval of Merck’s NOXAFIL®... Mar 17 2014
    Ligand Announces Highlights from Presentation at the 26th Annual Roth Capital Conference Mar 11 2014
    Captisol® Licensee Lundbeck Announces FDA Acceptance of NDA Submission for Carbamazepine IV Mar 10 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK